Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor

European Journal of Pharmacology

Volumn 460, Issue 2-3, 2003, Pages 163-170

  Bonifácio, Maria João ^a   Vieira Coelho, Maria Augusta ^a,b   Soares da Silva, Patrício ^a  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b Inst of Pharmacol and Therapeutics   (Portugal)

Author keywords

BIA 3 202; Catechol O methyltransferase inhibitor; Kinetic; Liver catechol O methyltransferase; Parkinson's disease

Indexed keywords

1 (3,4 DIHYDROXY 5 NITROPHENYL) 2 PHENYLETHANONE; ADRENALIN; ADRENALIN HYDROGEN TARTRATE; BENZENE DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; METADRENALIN; NITECAPONE; S ADENOSYLMETHIONINE; TOLCAPONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHRONOTHERAPY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG COMPETITION; DRUG SOLUBILITY; ENZYME ACTIVITY; ENZYME SUBSTRATE; GEL FILTRATION; IC 50; INCUBATION TIME; INHIBITION KINETICS; MALE; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; RAT; SAMPLE;

EID: 0037462481     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02879-0     Document Type: Article

References (28)

1. Axelrod J., Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233:1958;702-705.
2. Bonifati V., Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol. Ther. 81:1999;1-36.
3. Bradford M.M. A rapid method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
4. Cha S. Tight binding inhibitors: I. Kinetic behavior. Biochem. Pharmacol. 24:1975;2177-2185.
5. Guldberg H.C., Marsden C.A. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol. Rev. 27:1975;135-206.
6. Henderson P.J.F. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochem. J. 127:1972;321-333.
7. Jost W.H. Costs in the treatment of parkinsonism. J. Neurol. 247:2000;31-33.
8. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 59:2000;1233-1250.
9. Karhunen T., Tilgmann C., Ulmanen I., Julkunen I., Panula P. Distribution of catechol-O-methyltransferase enzyme in rat tissues. J. Histochem. Cytochem. 42:1994;1079-1090.
10. Kurth M.C., Adler C.H. COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology. 50:1998;S3-S14.
11. Lautala P., Ulmanen I., Taskinen J. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol. Pharmacol. 59:2001;393-402.
12. Learmonth D.A., Vieira-Coelho M.A., Benes J., Alves P.C., Borges N., Freitas A.P., Soares-da-Silva P. Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. J. Med. Chem. 45:2002;685-695.
13. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 34:1995;4202-4210.
14. Lundström K., Salminen M., Jalanko A., Savolainen R., Ulmanen I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol. 10:1991;181-189.
15. Männistö P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51:1999;593-628.
16. Motulsky H.G., Spannard P., Neubig R. GraphPad Prisms. 1994;GraphPad Prism Software, San Diego.
17. Nissinen E., Linden I.B., Schultz E., Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn-Schmiedeberg's Arch. Pharmacol. 346:1992;262-266.
18. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 7:1984;35-49.
19. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 56:2001;S1-S88.
20. Parada A., Loureiro A.I., Vieira-Coelho M.A., Hainzl D., Soares-da-Silva P. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation. Eur. J. Pharmacol. 420:2001;27-32.
21. Salminen M., Lundström K., Tilgmann C., Savolainen R., Kalkkinen N., Ulmanen I. Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene. 93:1990;241-247.
22. Schultz E., Nissinen E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem. Pharmacol. 38:1989;3953-3956.
23. Shepherd J., Clegg A. Entacapone as an adjunctive treatment to levodopa in Parkinson's disease. Development and Evaluation Committee Report. vol. 104:1999;1-50 The Wessex Institute for Health Research and Development, Southampton.
24. Vidgren J., Svensson L.A., Liljas A. Crystal structure of catechol-O-methyltransferase. Nature. 368:1994;354-358.
25. Vieira-Coelho M.A., Soares-da-Silva P. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br. J. Pharmacol. 117:1996;516-520.
26. Vieira-Coelho M.A., Soares-da-Silva P. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res. 821:1999;69-78.
27. William R., Hakala M.T. Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors. J. Biol. Chem. 264:1979;1204-1209.
28. Williams J.W., Morrison J.F. The kinetics of reversible tight-binding inhibition. Purich D.L. Methods in Enzymology. vol. 63:1979;437-467 Academic Press, New York.